Co-operation between Polpharma and RPG Life Sciences
05-10-2010
RPGLS and Polpharma announced their co-operation in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and in the management of the supply chain of selected high value APIs like clopidogrel bisulphate.
Polpharma, an integrated pharmaceutical company, leading generic pharma in Poland and a world-class manufacturer, is engaged in the development, manufacture, sale, and export of Active Pharmaceutical Ingredients (APIs) and of finished dosage forms. Polpharma is the largest producer of Active Pharmaceutical Ingredients in Poland and in the CEE.
RPG Life Sciences, formerly Searle (India) Ltd. is a full spectrum, world class, customer focused, innovative pharmaceutical company. Recently, its API business has been grown aggressively with a push towards introduction of High Value APIs in the EU and the US markets. The company’s Dosage Form business is also being rapidly expanded in the regulated markets.
“This move was essential for our strategic direction, and our solid determination to take action in new and creative ways” said Theodore Iliopoulos VP Operations and Fine Chemicals Business Unit at Polpharma group. “This cooperation scheme is putting ourselves in winning position, accelerating new product introductions, and unlocking additional efficiencies in our customers’ operations, helping lower their costs and increasing their marketplace”.
Ravi Soni, Chief Executive, RPG Life Sciences added that “the co-operation with Polpharma is a step towards many such alliances that the company is working on and this will expedite company’s growth in the highly profitable business segments whilst adding width and depth to our product portfolio”. “We are very excited with our co-operation with Polpharma and would like to expand the relationship to include several new molecules”, added Ravi Soni.